select a format

Single User License
USD 3500 INR 224420
Site License
USD 7000 INR 448840
Corporate User License
USD 10500 INR 673260

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"


Collagenase 3 Matrix Metalloproteinase-13 or MMP13 or EC 3.4.24.-Pipeline Review, H1 2016

Collagenase 3 Matrix Metalloproteinase-13 or MMP13 or EC 3.4.24.-Pipeline Review, H1 2016


  • Products Id :- GMDHC0116TDB
  • |
  • Pages: 31
  • |
  • June 2016
  • |
  • |
  Request for Sample Report

Executive Summary

Collagenase 3 (Matrix Metalloproteinase-13 or MMP13 or EC 3.4.24.)-Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Collagenase 3 (Matrix Metalloproteinase-13 or MMP13 or EC 3.4.24.)-Pipeline Review, H1 2016', provides in depth analysis on Collagenase 3 (Matrix Metalloproteinase-13 or MMP13 or EC 3.4.24.) targeted pipeline therapeutics.

The report provides comprehensive information on the Collagenase 3 (Matrix Metalloproteinase-13 or MMP13 or EC 3.4.24.), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Collagenase 3 (Matrix Metalloproteinase-13 or MMP13 or EC 3.4.24.) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape for Collagenase 3 (Matrix Metalloproteinase-13 or MMP13 or EC 3.4.24.)

The report reviews Collagenase 3 (Matrix Metalloproteinase-13 or MMP13 or EC 3.4.24.) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Collagenase 3 (Matrix Metalloproteinase-13 or MMP13 or EC 3.4.24.) targeted therapeutics and enlists all their major and minor projects

The report assesses Collagenase 3 (Matrix Metalloproteinase-13 or MMP13 or EC 3.4.24.) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Collagenase 3 (Matrix Metalloproteinase-13 or MMP13 or EC 3.4.24.) targeted therapeutics

Reasons To Buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Collagenase 3 (Matrix Metalloproteinase-13 or MMP13 or EC 3.4.24.)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Collagenase 3 (Matrix Metalloproteinase-13 or MMP13 or EC 3.4.24.) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
ankur [@] kenresearch.com
+91-9015378249
www.kenresearch.com

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Collagenase 3 (Matrix Metalloproteinase-13 or MMP13 or EC 3.4.24.) Overview 6

Therapeutics Development 7

Collagenase 3 (Matrix Metalloproteinase-13 or MMP13 or EC 3.4.24.)-Products under Development by Stage of Development 7

Collagenase 3 (Matrix Metalloproteinase-13 or MMP13 or EC 3.4.24.)-Products under Development by Therapy Area 8

Collagenase 3 (Matrix Metalloproteinase-13 or MMP13 or EC 3.4.24.)-Products under Development by Indication 9

Collagenase 3 (Matrix Metalloproteinase-13 or MMP13 or EC 3.4.24.)-Pipeline Products Glance 10

Early Stage Products 10

Collagenase 3 (Matrix Metalloproteinase-13 or MMP13 or EC 3.4.24.)-Products under Development by Companies 11

Collagenase 3 (Matrix Metalloproteinase-13 or MMP13 or EC 3.4.24.)-Therapeutics Assessment 13

Assessment by Monotherapy/Combination Products 13

Assessment by Mechanism of Action 14

Assessment by Route of Administration 15

Assessment by Molecule Type 17

Collagenase 3 (Matrix Metalloproteinase-13 or MMP13 or EC 3.4.24.)-Companies Involved in Therapeutics Development 19

Paradigm Biopharmaceuticals Limited 19

Pfizer Inc. 20

Takeda Pharmaceutical Company Limited 21

Collagenase 3 (Matrix Metalloproteinase-13 or MMP13 or EC 3.4.24.)-Drug Profiles 22

Pelladerm-Drug Profile 22

Product Description 22

Mechanism Of Action 22

R&D Progress 22

pentosan polysulfate sodium-Drug Profile 23

Product Description 23

Mechanism Of Action 23

R&D Progress 23

PF-152-Drug Profile 24

Product Description 24

Mechanism Of Action 24

R&D Progress 24

Small Molecules to Inhibit MMP for Myocardial Infarction-Drug Profile 25

Product Description 25

Mechanism Of Action 25

R&D Progress 25

Small Molecules to Inhibit MMP-13 for Osteoarthritis-Drug Profile 26

Product Description 26

Mechanism Of Action 26

R&D Progress 26

Small Molecules to Inhibit MMP-13 for Osteoarthritis Pain and Inflammation-Drug Profile 27

Product Description 27

Mechanism Of Action 27

R&D Progress 27

Collagenase 3 (Matrix Metalloproteinase-13 or MMP13 or EC 3.4.24.)-Dormant Projects 28

Collagenase 3 (Matrix Metalloproteinase-13 or MMP13 or EC 3.4.24.)-Discontinued Products 29

Appendix 30

Methodology 30

Coverage 30

Secondary Research 30

Primary Research 30

Expert Panel Validation 30

Contact Us 30

Disclaimer 31

List of Figures

Number of Products under Development for, H1 2016 7

Number of Products under Development by Therapy Area, H1 2016 8

Number of Products under Development by Top 10 Indication, H1 2016 9

Comparative Analysis by Early Stage Products, H1 2016 10

Assessment by Monotherapy/Combination Products, H1 2016 13

Number of Products by Stage and Mechanism of Actions, H1 2016 14

Number of Products by Routes of Administration, H1 2016 15

Number of Products by Stage and Routes of Administration, H1 2016 15

Number of Products by Molecule Types, H1 2016 17

Number of Products by Stage and Molecule Type, H1 2016 17

List of Tables

Number of Products under Development for, H1 2016 7

Number of Products under Development by Therapy Area, H1 2016 8

Number of Products under Development by Indication, H1 2016 9

Comparative Analysis by Early Stage Products, H1 2016 10

Number of Products under Development by Companies, H1 2016 11

Products under Development by Companies, H1 2016 12

Assessment by Monotherapy/Combination Products, H1 2016 13

Number of Products by Stage and Mechanism of Action, H1 2016 14

Number of Products by Stage and Route of Administration, H1 2016 16

Number of Products by Stage and Molecule Type, H1 2016 18

Pipeline by Paradigm Biopharmaceuticals Limited, H1 2016 19

Pipeline by Pfizer Inc., H1 2016 20

Pipeline by Takeda Pharmaceutical Company Limited, H1 2016 21

Dormant Projects, H1 2016 28

Discontinued Products, H1 2016 29

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Paradigm Biopharmaceuticals Limited

Pfizer Inc.

Takeda Pharmaceutical Company Limited

Collagenase 3 (Matrix Metalloproteinase-13 or MMP13 or EC 3.4.24.) Therapeutic Products under Development, Key Players in Collagenase 3 (Matrix Metalloproteinase-13 or MMP13 or EC 3.4.24.) Therapeutics, Collagenase 3 (Matrix Metalloproteinase-13 or MMP13 or EC 3.4.24.) Pipeline Overview, Collagenase 3 (Matrix Metalloproteinase-13 or MMP13 or EC 3.4.24.) Pipeline, Collagenase 3 (Matrix Metalloproteinase-13 or MMP13 or EC 3.4.24.) Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com